BRIEF-EMA's CHMP Starts Evaluating Marketing Authorisation Application For Merck's Lagevrio

European Medicines Agency: * EMA: EMA'S CHMP STARTED EVALUATING THE MARKETING AUTHORISATION APPLICATION FOR LAGEVRIO (MOLNUPIRAVIR): 23/11/2021

* EMA: EMA WILL ASSESS THE BENEFITS AND RISKS OF LAGEVRIO UNDER A REDUCED TIMELINE * EMA: COULD ISSUE OPINION WITHIN WEEKS IF DATA SUBMITTED ARE SUFFICIENTLY ROBUST AND COMPLETE TO SHOW THE EFFICACY, SAFETY AND QUALITY OF THE MEDICINE

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)